Published in
Elsevier, European Journal of Cancer, (94), p. 156-167
DOI: 10.1016/j.ejca.2018.02.011
Links
Tools
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Journal article published in 2018 by
Patrick Schöffski 
,
Agnieszka Wozniak ,
Michael G. Leahy,
Leahy Mg,
Steinar Aamdal,
Piotr Rutkowski ,
Sebastian Bauer ,
Stephan Richter,
Viktor Gruenwald,
Viktor Grünwald ,
Maria Debiec-Rychter,
Raf Sciot,
Birgit Geoerger,
Sandrine Marréaud,
Sandra Collette
and other authors.
,
Agnieszka Wozniak ,
Michael G. Leahy,
Leahy Mg,
Steinar Aamdal,
Piotr Rutkowski ,
Sebastian Bauer ,
Stephan Richter,
Viktor Gruenwald,
Viktor Grünwald ,
Maria Debiec-Rychter,
Raf Sciot,
Birgit Geoerger,
Sandrine Marréaud,
Sandra Collette
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Alveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.